Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk

Dow Jones

Jan 23

0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com)

(END) Dow Jones Newswires

January 22, 2026 21:11 ET (02:11 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605413442"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605413442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605413442?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605413442","market":"us","top_or_hot":-1,"title":"Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 21:11 ET (02:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-23 10:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 21:11 ET (02:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSL.SI","symbol_name":"莱佛士医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2605413442","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605413442","pubTimestamp":1769134260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BSL.SI":"莱佛士医疗"},"translate_title":"莱佛士医疗可能在2026-2027年维持盈利势头——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSL.SI":1.5},"content_text":"0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2026 21:11 ET (02:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}